IL-MINDBREEZE
With availability on the Google Cloud Marketplace, Mindbreeze offers another way for companies to use its AI-based knowledge management services without needing their own infrastructure.
Mindbreeze InSpire is now available for customers and partners on the popular online marketplaces (AWS Marketplace, Microsoft Azure Marketplace, and Google Cloud Marketplace) in addition to the existing deployment options, cloud, hosted by Mindbreeze, hybrid cloud or on-premises.
"By providing our knowledge management solution on different marketplaces, we support the respective strategy of the customer or partner, with full cost transparency. The computing power required for operation is obtained via the existing volume contract. The customer or partner receives the Mindbreeze license directly from us. We also support onboarding and provide Mindbreeze already tested and preconfigured. The protection of company data is regulated by the access rights in the Active Directory and by the choice of region," explains Daniel Fallmann, founder and CEO of Mindbreeze.
Thanks to the "bring-your-own-license" (BYOL) model, customers and partners can use their existing volume contracts with the online marketplaces to settle the infrastructure costs for Mindbreeze InSpire. A Mindbreeze license is also required. Since the customer's data is often already in the same online marketplace, there are no additional transfer costs for processing.
Mindbreeze InSpire is used by over 2,700 customers worldwide. The AI-based knowledge management solution uses generative AI (GenAI) to provide 360-degree views of entities such as customers, projects or products and enriches them with additional information. Additionally, Mindbreeze uses Retrieval Augmented Generation (RAG) to collect the necessary facts and uses a Large Language Model (LLM) to generate answers to users' questions via Mindbreeze InSpire AI Chat. Integration into the workplace is simple via add-ins in the prevailing system, for example email systems or online systems.
About Mindbreeze
Mindbreeze is a leading provider of AI-based knowledge management solutions with offices in Europe and North America and a global partner network.
The Mindbreeze InSpire product uses generative AI (GenAI) and other artificial intelligence (AI) methods to help companies analyze, understand, and efficiently network their business-critical information.
For more information, please visit www.mindbreeze.com or follow us on LinkedIn and Twitter @Mindbreeze.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523849062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches SP895BD-AP Smart Module, Powering the Next Generation of Intelligent IoT Applications5.1.2026 15:33:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, announced the official launch of its new-generation flagship smart module, the SP895BD-AP. Powered by the Qualcomm Dragonwing™ Q-8750 processor, the SP895BD-AP module boasts enhanced graphics processing capabilities, superior visual imaging effects, and advanced edge computing performance, meeting the requirements of high-end devices such as video conferencing systems, ultra-high-definition (UHD) displays, image synthesis equipment, computing power boards, smart retail terminals and smart home appliances. The SP895BD-AP redefines performance boundaries with its advanced hardware architecture. Powered by the Dragonwing Q-8750 processor built on a 3nm process, it features an 8-core high-performance Oryon™ CPU with a maximum frequency of 2×4.32 GHz + 6×3.53 GHz. Compared with the previous-generation (Series 8) chips, it achieves a 45% improvement in CPU performance and a 44% optimization in energy efficiency. This en
The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 15:00:00 CET | Press release
The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services. The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release
Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom